Genomic pathogen surveillance (service)

01Overview and value chain

Markers: [EC: IHR (2005) + EU HERA biosecurity framework | OECD: Biotech-health | Regulator: FDA (USA), EMA (European Union), NMPA (China)]

Genomic pathogen surveillance sequences pathogen genomes at scale to track viral and bacterial evolution, detect emerging variants and map transmission chains, feeding public health response decisions faster than case-count reporting alone. Ginkgo Bioworks’ Concentric platform runs the CDC’s Traveler-based Genomic Surveillance Program, sequencing pooled nasal-swab and wastewater samples from international travelers, and has expanded to new US airports including Miami and Chicago while partnering with Illumina to deploy biosurveillance technology globally, including a Rwanda government partnership. Oxford Nanopore Technologies’ portable MinION sequencers enable real-time field sequencing during outbreaks — its published workflow for Mpox virus sequencing is one current example of a technology previously deployed during Ebola and COVID-19 outbreak response. The Wellcome Sanger Institute runs the UK’s National Metagenomic Pathogen Surveillance Programme in partnership with the UK Health Security Agency (UKHSA), sharing initial surveillance data at the European Congress of Clinical Microbiology and Infectious Diseases (ESCMID). BGI Genomics operates large-scale pathogen genomic sequencing infrastructure in China, built out during the COVID-19 pandemic and continuing as part of the country’s infectious-disease response capacity. In India, the Rajiv Gandhi Centre for Biotechnology has been selected as the national next-generation-sequencing hub for metagenomic syndromic surveillance.

The key directions of genomic pathogen surveillance are:

1. Traveler-based genomic biosurveillance (Traveler-Based Genomic Surveillance): sequencing pooled samples from international travelers or at border points to detect emerging variants before they’re identified through clinical case reporting — Ginkgo Bioworks’ Concentric, the CDC airport program.
2. Portable field sequencing (Portable Genomic Sequencing): compact sequencers deployed directly at outbreak sites for real-time genomic data without shipping samples to a central lab — Oxford Nanopore Technologies.
3. National metagenomic surveillance programs (Metagenomic Pathogen Surveillance): government-partnered sequencing programs providing standing pathogen-genomics infrastructure for a country’s public health system — Wellcome Sanger Institute/UKHSA, Rajiv Gandhi Centre for Biotechnology.
4. Large-scale sequencing infrastructure (Genomic Surveillance Infrastructure): high-throughput national sequencing capacity built for pandemic response and sustained as ongoing surveillance capability — BGI Genomics.

Sectoral value chain

[sample collection (clinical/traveler)] ──> [sequencing (portable or centralized NGS)] ──> [bioinformatics lineage/variant calling]
                                                        │
                                          (public health reporting & alerting)
                                                        │
                                                        ▼
[international data sharing & coordination] <─── [outbreak response decision] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• Traveler-based biosurveillance (Traveler-Based Genomic Surveillance): pooled sampling at international travel hubs catches emerging variants circulating abroad before they appear in domestic clinical case data.
• Portable nanopore sequencing (Portable Genomic Sequencing): compact, field-deployable sequencers generate genomic data at the outbreak site itself, cutting the turnaround time a central-lab shipping step would add.
• National metagenomic infrastructure (Metagenomic Pathogen Surveillance): standing government-partnered sequencing hubs provide continuous pathogen-genomics capacity rather than one-off pandemic-response mobilization.

02US

The US anchors traveler-based genomic biosurveillance through a CDC-partnered private-sector platform, expanding airport coverage and international deployment.

Concentric by Ginkgo, CDC, Illumina

• Ginkgo Bioworks (Concentric): runs the CDC’s Traveler-based Genomic Surveillance Program, sequencing pooled samples from international travelers, with the program recently expanding to new international airports including Miami and Chicago.
• Illumina partnership: Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies internationally, including a government partnership in Rwanda supporting global health security.
• FDA/CDC framework: genomic pathogen surveillance in the US operates largely as a public-health-authority-partnered service rather than an FDA-regulated diagnostic product, governed by CDC program requirements and international IHR (2005) reporting obligations.

03CN

China operates large-scale pathogen genomic sequencing infrastructure built out during the COVID-19 pandemic, led by BGI Genomics.

BGI Genomics, NMPA

• BGI Genomics (华大基因): operates large-scale pathogen genomic sequencing infrastructure in China, expanded during the COVID-19 pandemic response and continuing as part of the country’s standing infectious-disease genomic-surveillance capacity.
• NMPA framework: pathogen genomic surveillance sequencing in China operates within the national public-health and NMPA regulatory framework for infectious-disease diagnostics and reporting.

04EU

The UK anchors Europe’s genomic pathogen surveillance capacity through both a national metagenomic surveillance program and a global portable-sequencing technology platform.

Wellcome Sanger Institute, Oxford Nanopore, UKHSA

• Wellcome Sanger Institute: runs the UK’s National Metagenomic Pathogen Surveillance Programme in partnership with the UK Health Security Agency (UKHSA), with initial surveillance data shared at the European Congress of Clinical Microbiology and Infectious Diseases (ESCMID).
• Oxford Nanopore Technologies: its portable MinION sequencers enable real-time genomic surveillance in the field, with a published workflow for Mpox virus sequencing illustrating current outbreak-response deployment.
• UKHSA/EU HERA framework: UK pathogen genomics surveillance operates under the UK Health Security Agency’s pathogen genomics programme, aligned with the broader EU Health Emergency Preparedness and Response Authority (HERA) biosecurity framework and International Health Regulations (IHR 2005) reporting.

05Leading companies and research institutes

06Tech stack and innovations

The stack pairs sequencing hardware (portable and centralized) with bioinformatics lineage-calling pipelines and public-health reporting workflows, converting raw genomic data into an actionable surveillance signal.

1. Traveler-based biosurveillance (Traveler-Based Genomic Surveillance):
   • Ginkgo Bioworks’ Concentric platform pools nasal-swab and wastewater samples from international travelers at airport sites, sequencing them to detect variants circulating abroad before they surface in domestic clinical case data, now expanded to additional US international airports.
2. Portable field sequencing (Portable Genomic Sequencing):
   • Oxford Nanopore Technologies’ MinION devices generate genomic sequence data directly at an outbreak site, with published workflows (including for Mpox) supporting rapid field deployment without shipping samples to a central lab.
3. National metagenomic surveillance infrastructure (Metagenomic Pathogen Surveillance):
   • The Wellcome Sanger Institute/UKHSA partnership and the Rajiv Gandhi Centre for Biotechnology’s designation as India’s national NGS hub both build standing, government-partnered sequencing capacity rather than one-off pandemic mobilization.
4. Large-scale sequencing infrastructure (Genomic Surveillance Infrastructure):
   • BGI Genomics’ pandemic-scale sequencing capacity, built out during COVID-19, continues as part of China’s ongoing infectious-disease genomic-surveillance capability.

07Value chains and production pipelines

Industrial pipeline of a genomic pathogen surveillance service (IHR 2005 / EU HERA biosecurity framework)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Sample collection      │ ───> │ 2. Sequencing              │
└───────────────────────────┘      └───────────────────────────┘
                                                   │
                                                   ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Public health          │ <─── │ 3. Bioinformatics &      │
│    reporting               │      │    lineage calling          │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Outbreak response      │ ───> │ 6. International data     │
│    decision                │      │    sharing                   │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Sample collection

Clinical specimens, pooled traveler nasal-swab samples at international travel hubs, or field samples collected at an active outbreak site are gathered for sequencing.

Stage 2: Sequencing

The pathogen genome is sequenced either on a portable field device (Oxford Nanopore’s MinION) or through centralized high-throughput NGS (BGI Genomics, Wellcome Sanger Institute), depending on speed and infrastructure requirements.

Stage 3: Bioinformatics and lineage calling

The raw sequence is assembled and classified against known pathogen lineages and variant databases, identifying whether it represents a previously characterized strain or a novel variant of concern.

Stage 4: Public health reporting

Lineage and variant calls are reported to public health authorities (CDC, UKHSA, NMPA-linked bodies, India’s national surveillance network) on a near-real-time basis to flag emerging threats.

Stage 5: Outbreak response decision

Public health authorities act on the surveillance report — issuing travel advisories, updating vaccine strain selection, or directing containment measures — using genomic data that leads clinical case-count reporting by days to weeks.

Stage 6: International data sharing

Validated sequence data is deposited into shared international genomic databases, supporting global coordination under International Health Regulations (IHR 2005) and regional frameworks such as the EU’s HERA biosecurity authority.